scholarly journals Breast cancer subtypes and the risk of distant metastasis at initial diagnosis: a population-based study

2018 ◽  
Vol Volume 10 ◽  
pp. 5329-5338 ◽  
Author(s):  
Weikai Xiao ◽  
Shaoquan Zheng ◽  
Anli Yang ◽  
Xingcai Zhang ◽  
Yutian Zou ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Distant Metastasis ◽  
Population Based ◽  
Initial Diagnosis ◽  
Breast Cancer Subtypes ◽  
Population Based Study ◽  
Cancer Subtypes

Distribution of molecular breast cancer subtypes among Algerian women and correlation with clinical and tumor characteristics: A population-based study

2015 ◽  
Vol 35 (2) ◽  
pp. 95-102 ◽  
Author(s):  
Farid Cherbal ◽  
Hadjer Gaceb ◽  
Chiraz Mehemmai ◽  
Insaf Saiah ◽  
Rabah Bakour ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Population Based ◽  
Breast Cancer Subtypes ◽  
Tumor Characteristics ◽  
Population Based Study ◽  
Cancer Subtypes

scholarly journals Population-Based Study on Cancer Subtypes, Guideline-Concordant Adjuvant Therapy, and Survival Among Women With Stage I–III Breast Cancer

2019 ◽  
Vol 17 (6) ◽  
pp. 676-686 ◽  
Author(s):  
Mei-Chin Hsieh ◽  
Lu Zhang ◽  
Xiao-Cheng Wu ◽  
Mary B. Davidson ◽  
Michelle Loch ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Adjuvant Therapy ◽  
Breast Cancer Subtype ◽  
Population Based ◽  
Survival Outcome ◽  
Stage I ◽  
Breast Cancer Subtypes ◽  
Population Based Study ◽  
Cancer Subtypes ◽  
Cancer Subtype

Background: Breast cancer subtype is a key determinant in treatment decision-making, and also effects survival outcome. In this population-based study, in-depth analyses were performed to examine the impact that breast cancer subtype and receipt of guideline-concordant adjuvant systemic therapy (AST) have on survival using a population-based cancer registry’s data. Methods: Women aged ≥20 years with microscopically confirmed stage I–III breast cancer diagnosed in 2011 were identified from the Louisiana Tumor Registry. Breast cancer subtypes were categorized based on hormone receptor (HR) and HER2 status. Guideline-concordant treatment was defined using the NCCN Guidelines for Breast Cancer. Logistic regression was applied to identify factors associated with guideline-concordant AST receipt. Kaplan-Meier survival curves were generated to compare survival among subtypes by AST receipt status, and a semiparametric additive hazard model was used to verify the factors impacting survival outcome. Results: Of 2,214 eligible patients, most (70.8%) were HR+/HER2– followed by HR–/HER2– (14.4%), and 78.6% received guideline-concordant AST. Compared with patients with the HR+/HER2+ subtype, women with other subtypes were more likely to be guideline-concordant after adjusting for sociodemographic and clinical variables. Women with the HR–/HER2+ or HR–/HER2– subtype had a higher risk of any-cause and breast cancer–specific death than those with the HR+/HER2+ subtype. Those who did not receive AST had an additional adjusted hazard of 0.0191 (P=.0001) in overall survival and 0.0126 (P=.0011) in cause-specific survival compared with those who received AST. Conclusions: Most patients received guideline-concordant AST, except for those with the HR+/HER2+ subtype. Patients receiving guideline-adherent adjuvant therapy had better survival outcomes across all breast cancer subtypes.

scholarly journals Ten-year recurrence rates for breast cancer subtypes in the Netherlands: A large population-based study

2018 ◽  
Vol 144 (2) ◽  
pp. 263-272 ◽  
Author(s):  
Marissa C. van Maaren ◽  
Linda de Munck ◽  
Luc J.A. Strobbe ◽  
Gabe S. Sonke ◽  
Pieter J. Westenend ◽  
...  
Keyword(s):  
Breast Cancer ◽  
The Netherlands ◽  
Large Population ◽  
Population Based ◽  
Breast Cancer Subtypes ◽  
Recurrence Rates ◽  
Population Based Study ◽  
Cancer Subtypes

scholarly journals Associations between sociodemographic and clinicopathological factors and breast cancer subtypes in a population-based study

2015 ◽  
Vol 26 (12) ◽  
pp. 1737-1750 ◽  
Author(s):  
Adana A. M. Llanos ◽  
Sheenu Chandwani ◽  
Elisa V. Bandera ◽  
Kim M. Hirshfield ◽  
Yong Lin ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Population Based ◽  
Breast Cancer Subtypes ◽  
Clinicopathological Factors ◽  
Population Based Study ◽  
Cancer Subtypes

Distribution and prognosis of molecular breast cancer subtypes defined by immunohistochemical biomarkers in a Spanish population-based study

2013 ◽  
Vol 130 (3) ◽  
pp. 609-614 ◽  
Author(s):  
M. Puig-Vives ◽  
M.J. Sánchez ◽  
J. Sánchez-Cantalejo ◽  
A. Torrella-Ramos ◽  
C. Martos ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Population Based ◽  
Breast Cancer Subtypes ◽  
Spanish Population ◽  
Population Based Study ◽  
Cancer Subtypes

scholarly journals Risk factors of distant metastasis after surgery among different breast cancer subtypes: a hospital-based study in Indonesia

2020 ◽  
Vol 18 (1) ◽  
Author(s):  
Sumadi Lukman Anwar ◽  
Widya Surya Avanti ◽  
Andreas Cahyo Nugroho ◽  
Lina Choridah ◽  
Ery Kus Dwianingsih ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Risk Factors ◽  
Distant Metastasis ◽  
Breast Cancer Subtypes ◽  
Cancer Subtypes

Time to brain metastasis (TTBM) from initial diagnosis of distant metastasis in breast cancer: Prediction of TTBM according to breast cancer subtypes and treatment effect.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 644-644 ◽  
Author(s):  
Yeon Hee Park ◽  
Hee Kyung Ahn ◽  
Silvia Park ◽  
Chi Hoon Maeng ◽  
Su Jin Lee ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Brain Metastasis ◽  
Treatment Effect ◽  
Distant Metastasis ◽  
Therapeutic Strategy ◽  
Medical Center ◽  
Metastatic Breast ◽  
Initial Diagnosis ◽  
Cancer Subtypes ◽  
Cancer Prediction

644 Background: Brain metastasis (BM) from breast cancer (BC) is a growing problem. About 10-15% patients with metastatic breast cancer (MBC) developed BM, with a 1 year survival of 20%. Currently, one-third of MBC patients with either HER2+ve tumors or triple negative BC (TNBC) tumors develop brain metastases. We hypothesized that MBC patients may predispose to BM differently during the disease courses according to BC subtype and treatment. We analyzed TTBM from initial diagnosis of distant metastasis how BC subtypes and treatment affect on TTBM. Methods: We retrospectively investigated 189 consecutive patients who were diagnosed with BM from BC between 2000 and 2009 at Samsung Medical Center. We analyzed TTBM according to BC subtypes and treatment effect. Results: The median age of 189 BM patients from BC was 48 (range 26-87) years. The numbers of patients with hormone receptor (HR)+ve and HER2-ve, HER2+ve irrespective of HR status, and TNBC were 43 (22.8%), 88 (46.6%), and 58 (30.7%), respectively. Median TTBM of all 189 patients was 10.4 (95% CI, 7.7-13.1) months. We analyzed TTBC into four groups considering BC subtypes and treatment; HR+ve/HER2-ve (n=43), HER2+ve with trastuzumab (T) (n=59), HER2+ve without T (n=29), and TNBC patients (n=58). The median TTBMs for each group were 17.7 months, 13.8 months, 4.3 months, and 2.9 months, respectively (p=0.002). BM as an initial site of distant metastasis was much more common in HER2+ve without T and TNBC patients than in the other patients’ groups (40.2% vs 20.6%, p= 0.003). Conclusions: TTBMs were much shorter in patients with HER2+ve without T and TNBCs than in other BC patients. Different approaches for evaluation and therapeutic strategy for BM at the time of distant metastasis may be considered for these populations.

Sign in / Sign up

Export Citation Format

Share Document